MELISA Institute Genomics & Proteomics Research
CompanyChile
MELISA Institute Genomics & Proteomics Research develops one asset, in phase 2 (epigallocatechin gallate in COVID-19). Mostly supplement acting on Oxidative stress and ROS signalling and inflammation; based in Chile.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Green tea polyphenol with antioxidant, anti-inflammatory, and antiviral properties
Phase 2, Supplement, Oxidative stress and ROS signalling, Inflammation, COVID-19, sars cov2
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials1
- Signals2
- Similar companies6